Michele Tagliati, MD
Neurology · Los Angeles, CANPI 1134190457
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $183,782 of the $292,817 with a category attached, or 62.8%. 22 manufacturers reported payments, led by Boston Scientific at 51.8% of the total. Reporting peaked in 2019 at $89,253 and has fallen 55.5% since, to $39,734 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $578.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$152K
- Medtronic$45K
- Abbott$36K
- AbbVie$27K
- Genentech USA, Inc.$7K
- MDD US Operations, LLC$5K
- plus $20K from 16 others
Across 170 payments — averaging $12,877 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$686K
- Novo Nordisk$523K
- Biogen$385K
- AbbVie$371K
- Takeda Pharmaceuticals U.S.A., Inc.$104K
- Boston Scientific$60K
- plus $61K from 3 others
What the payments were for
- Consulting fees$76,06426%
- Speaking & faculty fees$183,78263%
- Travel & lodging$17,7966%
- Food & beverage$15,0485%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 262 | $151,698 |
| Medtronic(2 entities) | 65 | $44,805 |
| Abbott | 53 | $36,142 |
| AbbVie(2 entities) | 42 | $27,161 |
| Genentech USA, Inc. | 8 | $7,476 |
| MDD US Operations, LLC | 15 | $5,448 |
| F. Hoffmann-la Roche AG | 2 | $5,123 |
| Tanabe Pharma America, Inc. | 9 | $4,644 |
| Acorda Therapeutics, Inc | 11 | $4,353 |
| Kyowa Kirin, Inc. | 1 | $2,250 |
| Biogen | 1 | $1,013 |
| Sage Therapeutics, LLC | 10 | $832 |
| Merz Pharmaceuticals, LLC | 8 | $744 |
| Teva Pharmaceuticals USA, Inc. | 4 | $338 |
| Merz North America, Inc. | 4 | $281 |
| Insightec,inc | 1 | $146 |
| Acadia Pharmaceuticals Inc | 2 | $117 |
| Neurocrine Biosciences, Inc. | 1 | $111 |
| Life Molecular Imaging Ltd | 4 | $91 |
| Cala Health, Inc. | 1 | $31 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL DBS$80,936
- VERCISE$51,908
- ACTIVA$42,425
- Neuromodulation Dspsbls and Accs$19,601
- BOTOX$16,018
- INFINITY$13,818
- INBRIJA$3,725
- GENERAL - THERAPIES$3,263
- APOKYN$3,017
- NOURIANZ$2,250
- Duopa$1,600
- Infinity DBS Pulse Generators$1,545
- SPECTRA WAVEWRITER$1,500
- XEOMIN$528
- PROCLAIM$327
- MYOBLOC$257
- Xadago$257
- PERCEPT PC BRAINSENSE$231
- Exablate$146
- Austedo XR$140
How this compares
$292,817 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 47 | $65,301 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 464 | $19,926 |
| Trazodone Hcl | 207 | $2,802 |
| Midodrine Hcl | 27 | $2,433 |
| Entacapone | 13 | $1,962 |
| Clonazepam | 103 | $772 |
| Propranolol Hcl ErPropranolol Hcl | 17 | $745 |
| Gabapentin | 38 | $561 |
| Fludrocortisone Acetate | 33 | $411 |
| Lorazepam | 23 | $308 |
| Mirtazapine | 26 | $293 |
| Escitalopram Oxalate | 12 | $206 |
| Baclofen | 19 | $143 |
| Clozapine | 18 | $137 |
| Donepezil Hcl | 17 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $14 | $65,30147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.